Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

IMPATH Delisted by Nasdaq, Under Investigation by SEC

Onetime high-flying pathology company now faces incredible scrutiny on almost all fronts

EFFECTIVE AUGUST 27, Nasdaq Stock Market, Inc. delisted the stock of IMPATH, Inc. Less than a week earlier, IMPATH had disclosed that it was under investigation by the Securities and Exchange Commission (SEC). IMPATH can truly be described as a company under siege. It is short of cash, under regulatory investigation, and defending itself from …

IMPATH Delisted by Nasdaq, Under Investigation by SEC Read More »

To access this post, you must purchase The Dark Report.



You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.